References

Albin, R. L., Young, A. B., & Penney, J. B. (1989). The functional anatomy of basal ganglia disorders. *Trends in Neurosciences*, *12*, 366–375.

Alexander, G. E., & Crutcher, M. D. (1990). Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. *Trends Neuroscience*, *13*, 266–271.

Alexander, G. E., DeLong, M. R., & Strick, P. L. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. *Annual Review of Neuroscience*, *9*, 357–381.

Anonymous (1989). DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. Parkinson study group. *Archives of Neurology*, *46*, 1052–1060.

Bergman, H., Wichmann, T., & DeLong, M. R. (1990). Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. *Science*, *249*, 1436–1438.

Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiology of Aging*, *24*, 197–211.

Breakefield, X. O., Blood, A. J., Li, Y., Hallett, M., Hanson, P. I., & Standaert, D. G. (2008). The pathophysiological basis of dystonias. *Nature Reviews Neuroscience*, *9*, 222–234.

Brouillet, E., Conde, F., Beal, M. F., & Hantraye, P. (1999). Replicating Huntington's disease phenotype in experimental animals. *Progress in Neurobiology*, *59*, 427–468.

Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., et al. (2007). 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. *Nature*, *447*, 1081–1086.

Conn, P. J., Battaglia, G., Marino, M. J., & Nicoletti, F. (2005). Metabotropic glutamate

receptors in the basal ganglia motor circuit. *Nature Reviews Neuroscience*, *6*, 787–798.

DeLong, M. R., & Wichmann, T. (2007). Circuits and circuit disorders of the basal ganglia. *Archives of Neurology*, *64*, 20–24.

Desplats, P., Lee, H. J., Bae, E. J., Patrick, C., Rockenstein, E., Crews, L., et al. (2009). Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. *Proceedings of the National Academy of Sciences of the United States of America*, *106*, 13010–13015.

Fernandez-Alvarez, E. (2010). Dystonia. The paediatric perspective. *European Journal of Neurology*, *17*(Suppl. 1), 46–51.

Ferre, S., Lluis, C., Justinova, Z., Quiroz, C., Orru, M., Navarro, G., et al. (2010). Adenosine-cannabinoid receptor interactions. Implications for striatal function. *British Journal of Pharmacology*, *160*, 443–453.

Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W. Y., DuMouchel, W., Kao, R., et al. (2001). Transplantation of embryonic dopamine neurons for severe Parkinson's disease. *The New England Journal of Medicine*, *344*, 710–719.

Galvan, A., & Wichmann, T. (2007). GABAergic circuits in the basal ganglia and movement disorders. Progress in brain research. *Progress in Brain Research*, *160*, 287–312.

Greenamyre, J. T., Eller, R. V., Zhang, Z., Ovadia, A., Kurlan, R., & Gash, D. M. (1994). Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. *Annals of Neurology*, *35*, 655–661.

H. s. D. C. R. Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell*, *72*, 971–983.

Johnson, K. A., Conn, P. J., & Niswender, C. M. (2009). Glutamate receptors as therapeutic targets for Parkinson's disease. *CNS and Neurological Disorders, 8,* 475–491.

Martella, G., Tassone, A., Sciamanna, G., Platania, P., Cuomo, D., Viscomi, M. T., et al. (2009). Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: Role of endogenous acetylcholine. *Brain: A Journal of Neurology, 132*, 2336–2349.

McNaught, K. S., Olanow, C. W., Halliwell, B., Isacson, O., & Jenner, P. (2001). Failure of the ubiquitin–proteasome system in Parkinson's disease. *Nature Reviews Neuroscience, 2*, 589–594.

Novak, M. J., & Tabrizi, S. J. (2010). Huntington's disease. *BMJ 340*: 34–40. c3109.

Olanow, C. W., & Prusiner, S. B. (2009). Is Parkinson's disease a prion disorder? *Proceedings of the National Academy of Sciences of the United States of America*, *106,* 12571–12572.

Pisani, A., Bernardi, G., Ding, J., & Surmeier, D. J. (2007). Re–emergence of striatal cholinergic interneurons in movement disorders. *Trends in Neurosciences*, *30*, 545–553.

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science, 276*, 2045–2047.

Pont–Sunyer, C., Marti, M. J., & Tolosa, E. (2010). Focal limb dystonia. *European Journal of Neurology*, *17*(Suppl. 1), 22–27.

Ramaswamy, S., McBride, J. L., & Kordower, J. H. (2007). Animal models of Huntington's disease. *ILAR Journal/National Research Council, Institute of Laboratory Animal Resources*, *48*, 356–373.

Reddy, P. H., Williams, M., & Tagle, D. A. (1999). Recent advances in understanding the pathogenesis of Huntington's disease. *Trends in Neurosciences*, *22*, 248–255.

Reiner, A., Albin, R. L., Anderson, K. D., D'Amato, C. J., Penney, J. B., & Young, A. B. (1988). Differential loss of striatal projection neurons in Huntington disease. *Proceedings of the National Academy of Sciences of the United States of America*, *85*, 5733–5737.

Rice, M. E., & Cragg, S. J. (2008). Dopamine spillover after quantal release: Rethinking dopamine transmission in the nigrostriatal pathway. *Brain Research Reviews*, *58*, 303–313.

Schiffmann, S. N., Fisone, G., Moresco, R., Cunha, R. A., & Ferre, S. (2007). Adenosine A2A receptors and basal ganglia physiology. *Progress in Neurobiology*, *83*, 277–292.

Schmidt, A., & Klein, C. (2010). The role of genes in causing dystonia. *European Journal of Neurology*, *17*(Suppl. 1), 65–70.

Schultz, W. (1998). The phasic reward signal of primate dopamine neurons. *Advances in Pharmacology*, *42*, 686–690.

Schwarcz, R., Guidetti, P., Sathyasaikumar, K. V., & Muchowski, P. J. (2010). Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. *Progress in Neurobiology*, *90*, 230–245.

Schwarzschild, M. A., Agnati, L., Fuxe, K., Chen, J. F., & Morelli, M. (2006). Targeting adenosine A2A receptors in Parkinson's disease. *Trends in Neurosciences*, *29*, 647–654.

Smith, Y., & Villalba, R. (2008). Striatal and extrastriatal dopamine in the basal ganglia: An overview of its anatomical organization in normal and Parkinsonian brains. *Movement Disorders: Official Journal of the Movement Disorder Society*, *23*(Suppl. 3), S534–S547.

Wichmann, T. (2008). Commentary: Dopaminergic dysfunction in DYT1 dystonia. *Experimental*

Neurology, *212*, 242–246.

Wichmann, T., & DeLong, M. R. (2007). Anatomy and physiology of the basal ganglia: Relevance to Parkinson's disease and related disorders. In W Koller & E Melamed (Eds.), *Handbook clinneurol* (pp. 1–18). New York, NY: Elsevier.